Last reviewed · How we verify

NCT05437471

Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure

Completed NA Last updated 29 June 2022
What this trial tests

NA trial testing GNRH Analoge, Duphaston, Letrozole in Miscarriage, Recurrent in 39 participants. Completed in 30 May 2022.

Timeline
1 January 2020
Primary endpoint
30 December 2021
30 May 2022

Quick facts

Lead sponsorUniversiti Kebangsaan Malaysia Medical Centre
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment39
Start date1 January 2020
Primary completion30 December 2021
Estimated completion30 May 2022
Sites1 location across Malaysia

Drugs / interventions tested

Conditions studied

Sponsor

Universiti Kebangsaan Malaysia Medical Centre — full company profile →

Who can join

Adults 18 to 40, female only, with Miscarriage, Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the abv3-integrin expression in endometrium tissue among RIF women between the GnRH analogue with Aromatase Inhibitor (Group A) , GnRH analogue with progesterone (Group B) and GnRH analogue alone as control group (Group C)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Miscarriage, Recurrent

Currently open trials in the same condition.

Other Universiti Kebangsaan Malaysia Medical Centre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05437471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing